IGM Biosciences Inc (IGM Biosciences) operates as a biotechnology company that develops novel antibodies for the treatment of cancer and other diseases. The company's pipeline product portfolio includes IGM-2323is an IgM-based CD20 x CD3 bispecific antibody T cell engager, IGM-8444 is an IgM antibody targeting Death Receptor, IGM-7354 is a targeted IL-15 immune stimulating antibody and IGM-2644 a T cell engaging IgM antibody targeting CD38 for the treatment of patients with multiple myeloma. It utilizes IgM and IgA antibodies technology for developing its products. IGM Biosciences is headquartered in Mountain View, California, the US.
Headquarters
United States of America
Address
325 E Middlefield Rd, Mountain View, California, 94043-4003
Website
igmbio.com
Telephone
1 650 9657873
No of Employees
224
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IGMS (NASD)
Revenue (2022)
$2.1M
99.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-11.4%
(2022 vs 2021)
Market Cap*
$540.8M
Net Profit Margin (2022)
XYZ
44.1%
(2022 vs 2021)
* As of and is in US$
IGM Biosciences Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| IGM-2323 |
| IGM-8444 |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Plans/Strategy | In November, the company announced its plans to raise up to US$400 million in public offering of securities. |
| 2023 | Stock Listings/IPO | In June, the company announced its plans to offer and sell an aggregate of US$100.0 million of shares of its common stock. |
| 2023 | Regulatory Approval | In May, the company announced that the U.S. Food and Drug Administration (FDA) cleared two investigational new drug applications for imvotamab. |
Competitor Comparison
| Key Parameters | IGM Biosciences Inc | Athenex Inc | SELLAS Life Sciences Group Inc | Adastra Pharmaceuticals Inc (Inactive) | CoImmune Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Mountain View | Buffalo | New York | Carlsbad | Durham |
| State/Province | California | New York | New York | California | North Carolina |
| No. of Employees | 224 | 269 | 17 | - | 49 |
| Entity Type | Public | Private | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Fred M. Schwarzer | Chief Executive Officer; Director; President | Executive Board | 2003 | 71 |
| Misbah Tahir | Chief Financial Officer | Senior Management | 2019 | 48 |
| Chris H. Takimoto, M.D., Ph.D. | Chief Medical Officer | Senior Management | 2021 | 64 |
| Carrie Brodmerkel | Chief Scientific Officer | Senior Management | - | - |
| Bruce Keyt, Ph.D. | Chief Scientific Officer | Senior Management | 2012 | 69 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward